Phase 3 trial data show a synthetic semaglutide injection provides glycemic control comparable to Ozempic in patients with type 2 diabetes.
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patientsOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE ...
BACKGROUND: The World Health Organization recommends echocardiographic screening and secondary prophylaxis for rheumatic ...
Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy ---- Weight category improveme ...
Escape, Shannon, Strix, PentAGI, and Claude against a modern vulnerable application. Learn more about their detection rates, ...
The FDA has granted accelerated approval to Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for pediatric and ...
First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity ---- European Commission grants authorization in adults ...
Can a 2022 Toyota RAV4 survive 120,000 miles of Arizona heat? Phoenix owner Joseph Jarlego proves it can. With zero ...
European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment -- BOSTON, May 01, 2026 (GLOBE ...
A recent study found a possible association between severe male infertility and an increased risk of thyroid and colorectal ...
Pfizer Inc. today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results